TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Next-Day Residual Effects of Gabapentin, Diphenhydramine and Triazolam on Simulated Driving Performance in Normal Volunteers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy males and females of non-childbearing potential, 25-55 years of age~* Valid driver's license~Exclusion Criteria:~* Psychiatric disorder~* Recent history of clinically significant neurological disorder, such as seizures, stroke, multiple sclerosis, or head trauma~* Recent histroy or current treatment for sleep disorder

- Gender: ALL
- Minimum Age: 25 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Arm A (Type: EXPERIMENTAL): None
- Arm B (Type: EXPERIMENTAL): None
- Arm C (Type: ACTIVE_COMPARATOR): None
- Arm D (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Neuroprotection With Phenytoin in Optic Neuritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of acute optic neuritis~* Visual acuity in affected eye ≤ 6/12~* Corrected vision in normal eye ≥ 6/6~* No history of optic neuritis or other ocular disease in either eye~* ≤ 14 days since onset of visual loss~Exclusion Criteria:~* Contraindication or known allergy to Phenytoin~* Contraindication to MRI~* Use of a calcium channel or sodium channel blocker in the past 2 months~* Corticosteroid use in the past 2 months~* Tysabri infusion in the past 3 months~* MS with major temperature dependent disability~* Relapsing remitting MS of greater than 10 yrs duration or EDSS\>3~* Pregnancy~* Breast Feeding~* Significant cardiac, renal or liver abnormalities

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- phenytoin (Type: EXPERIMENTAL): active arm of trial 1:1 allocation active versus placebo
- placebo (Type: PLACEBO_COMPARATOR): 1:1 allocation active versus placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study Of Efficacy And Safety Of Fesoterodine In Vulnerable Elderly Subjects With Overactive Bladder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* male or female subjects 65 years of age or older~* OAB symptoms for at least 3 months~* score 3 or greater on Vulnerable Elderly Survey (VES-13)~* adequate mobility for independent toileting~* mean number of at least 2 UUI episodes per 24 hours~* mean urinary frequency of 8 or more micturitions per 24 hours~* able to independently complete the bladder diaries~Exclusion Criteria:~* PVR urinary volume greater than 200 ml~* MMSE score less than 20~* greater than 15 UUI episodes per 24 hours~* creatinine clearance less than 30 ml/min~* an average resting heart rate of greater than or equal to 90 beats per minute

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Fesoterodine (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: BELIEF (Bevacizumab and ErLotinib In EGFR Mut+ NSCLC)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18 years~* ECOG performance status 0-2~* Adequate haematological function, coagulation, liver function and renal function~* Pathological diagnosis of predominantly non-squamous, non-small-cell lung cancer (NSCLC)~* TNM version 7 stage IV disease including M1a (malignant effusion) or M1b (distant metastasis), or locally advanced disease not amenable to curative treatment (including patients progressing after radiochemotherapy for stage III disease)~* Measurable or evaluable disease (according to RECIST 1.1 criteria).~* Centrally confirmed EGFR exon 19 deletion (del19) or exon 21 mutation (L858R)~Exclusion Criteria:~* Patients with increased risk of bleeding~* Patients with clinically significant cardiovascular diseases~* Patients with a history of thrombosis or thromboembolism in the 6 months prior to treatment~* Patients with gastrointestinal problems~* Patients with neurologic problems~* Patients who have had in the past 5 years any previous or concomitant malignancy EXCEPT adequately treated basal or squamous cell carcinoma of the skin, in situ carcinoma of the cervix or bladder, in situ breast carcinoma.~* Patients with any known significant ophthalmologic anomaly of the ocular surface~* Patients who received prior chemotherapy for metastatic disease~* Patients who received previous treatment for lung cancer with drugs targeting EGFR or VEGF~* Pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Erlotinib plus bevacizumab (Type: EXPERIMENTAL): Patients will be treated with erlotinib and bevacizumab. Bevacizumab: 15 mg/kg i.v. on day 1 of each 3-week cycle (+/- 3 days) Erlotinib: 150 mg p.o., daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Preventing Urinary Tract Infection Post-Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Presenting at the gynecology clinic for a pre-operatory visit~2. Ability to give informed consent~3. Willing to take cranberry capsules for up to 6 weeks~4. 18 of age or older~Exclusion Criteria:~1. Pregnancy~2. History of nephrolithiasis~3. History of allergy to cranberry~4. Patient on anticoagulant medicine to be re-started during the 4-6 weeks after surgery~5. Less than 18 years old

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cranberry powder capsules (Type: EXPERIMENTAL): TheraCran® cranberry: based upon proanthocyanidin content, the four cranberry capsules are equivalent to two 8-ounce servings of cranberry juice.~Participants were directed to take two capsules by mouth twice each day (once in the morning and once in the evening) starting at time of discharge for 4-6 weeks, or until their return for their post-operative doctor's visit. Participants were instructed to drink an 8 oz glass of water while taking the capsule with or without food.
- Placebo capsules (Type: PLACEBO_COMPARATOR): Placebo: participants were directed to take two capsules by mouth twice each day (once in the morning and once in the evening) starting at time of discharge for 4-6 weeks, or until their return for their post-operative doctor's visit. Participants were instructed to drink an 8 oz glass of water while taking the capsule with or without food.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effectiveness of Stepped Care Versus Best Available Care for Bulimia Nervosa

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of bulimia nervosa~Exclusion Criteria:~* Weight less than 85% of ideal~* Current substance abuse or dependence~* Pregnant~* Currently receiving psychotherapy

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Stepped Care (Type: EXPERIMENTAL): Participants will receive guided self-help with nine clinician checkups, followed by fluoxetine if nonresponsive, followed by cognitive behavioral therapy if still nonresponsive.
- Cognitive Behavioral Therapy (Type: ACTIVE_COMPARATOR): Participants will receive 20 sessions of cognitive behavioral therapy with the addition of fluoxetine at interim points.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect and Safety Study of Atorvastatin to Treat Chronic Subdural Hematoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age ≥ 18 and \<90 years old, male or female;~2. CT scan reveals supratentorial, unilateral or bilateral chronic subdural hematoma (MRI scan is warranted if diagnosis is difficult);~3. Markwalder's Grading Scale and Glasgow Coma Scale (MGS-GCS)\<Grade 3;~4. Attending physician makes a judgment that cerebral hernia would not occur and surgical operation might not be performed in a short time. Conservative treatment is adopted;~5. Patients have never undergo surgery on the hematoma~6. Patient fully understood the nature of the study, and voluntarily participates and signs informed consent.~Exclusion Criteria:~1. Allergic to the statin or its ingredients~2. Cerebral herniation might occur at any time;~3. Hematoma leads to herniation and warrants surgical operation.~4. Hematoma caused by tumors, blood and other known comorbidities;~5. Abnormal liver function~6. Uncontrolled hepatitis and other liver diseases, as well as suffering from other disease may interfere the study~7. Patients have been on oral Statin treatment for a long time.~8. Patients have been on oral Steroids treatment for a long time.~9. Participate in clinical trials in the past four weeks;~10. Pregnant or breastfeeding~11. Failure of completing the trial by poor compliance;~12. For any reason, the researchers believe that the case is not suitable for inclusion.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Atorvastatin (Type: EXPERIMENTAL): atorvastatin：20 mg (every evening orally) for 8 weeks
- placebo (Type: PLACEBO_COMPARATOR): placebo:20 mg (every evening orally) for 8 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Of The Safety And Efficacy Of Conversion From A CNI To Sirolimus In Renally-Impaired Heart Transplant Recipients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Cardiac transplant recipients age 18 years or older receiving cyclosporine or tacrolimus since the time of transplant.~* 12 months after cardiac transplantation but less than 96 months post-transplantation.~Exclusion Criteria:~* Multiple-organ transplant recipients (such as heart-lung, heart-kidney, or heart after kidney transplant recipients).~* Prior or current use of sirolimus or everolimus unless administration was part of a CNI holiday lasting no more than 10 days.~* History of acute rejection within the last 3 months, malignancy within the last 5 years (except for adequately treated basal cell or squamous cell carcinoma of the skin), and human immunodeficiency virus (HIV) patients.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Group 1: Continuation of CNI regimen
- 2 (Type: EXPERIMENTAL): Group 2: (CNI-Free) Conversion to SRL-based regimen

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Prospective Study of Human Bone Adaptation Using a Novel in Vivo Loading Model

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Female~* Age 21-40~* Body Mass Index \[18-29\]~* 9-14 menstrual cycles/year~* Dual energy X-ray Absorptiometry total radius bone mineral density (BMD) T-score \[-2.5-+1\]~* Free of endocrinopathies~* No known thyroid, vitamin D, or calcium abnormalities~Exclusion Criteria:~* Fracture to wrist \<5 years ago~* Wrist Arthritis~* Injury to the non-dominant elbow or shoulder \<5 years ago~* Diabetes~* Severe disabling conditions~* Cancer \<5 years ago~* Metabolic bone disease~* Androgen, estrogen, progesterone, calcitonin, Selective Estrogen Receptor Modulators, Parathyroid hormone, gonadotropin-releasing hormone or analogs used \<6 months ago~* Corticosteroids \<3 months ago~* Bisphosphonates or fluoride \<3 years ago~* Cardiovascular/pulmonary disease~* Uncontrolled hypertension~* Regular Tobacco use~* Marijuana use \>1 time/week~* Alcohol \>4 drinks/day~* Pregnancy or lactation \<2 years ago~* Plan to become pregnant or donate eggs within 1 year~* Depot medroxyprogesterone acetate contraceptive \<6 months ago~* Current participation in upper extremity loading sports (gymnastics, tennis, softball, hockey) \>2 times/month~* Low calcium intake (avoiding dairy products without taking calcium supplement)

- Gender: FEMALE
- Minimum Age: 21 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- Low Magnitude (Type: EXPERIMENTAL): voluntary forearm compression by leaning onto the palm of the hand with low target strain
- High Magnitude (Type: EXPERIMENTAL): voluntary forearm compression by leaning onto the palm of the hand with high target strain
- Low Rate (Type: EXPERIMENTAL): voluntary forearm compression by leaning onto the palm of the hand with low strain rate (task performed slowly and evenly)
- High Rate (Type: EXPERIMENTAL): voluntary forearm compression by leaning onto the palm of the hand with high strain rate (task performed as quickly as possible, with a bump)
- Control (Type: NO_INTERVENTION): observation only

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Stepped Care for Children After Trauma: Optimizing Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Parent/Guardian-child dyads enrolled.~Inclusion Criteria:~1. Child experienced at least one traumatic event after the age of 36 months~2. Child age 4-6 must meet at least four PTSD symptoms and children age 7 to 12 must meet at least five PTSD symptoms with at least one symptom in re-experiencing or one symptom in avoidance~3. At enrollment, the child must be between 4-12 years of age~4. The parent/guardian must be willing and able to participate in the treatment and complete informed consent~Exclusion Criteria:~1. Psychosis, mental retardation, autism spectrum disorder in the child or any condition that would limit the caregiver's ability to understand CBT and the child's ability to follow instructions~2. Parent has had substance use disorder (SUD) within the past 3 months.~3. Child or parent is suicidal~4. Child or parent is not fluent in English~5. Child is currently taking psychotropic medication and is not on a stable medication regimen for at least 4 weeks prior to admission to the study. For stimulants or benzodiazepines, the medication regimen must be stable for 2 weeks. If appropriate, a delayed entry will be allowed so that once a child is on a stable dosage the child may be enrolled in the study.~6. Child is receiving trauma-focused psychotherapy during study treatment.~7. Parent/caregiver who would be treatment participant was the perpetrator, or the child was perpetrated by a person who still lives in the home~8. Child is having unsupervised face-to-face contact with the identified perpetrator~9. Siblings

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- Stepped Care TF-CBT (Type: EXPERIMENTAL): Stepped Care TF-CBT consist of two steps. Step One is a parent-led therapist-assisted treatment and Step Two is standard TF-CBT.
- Standard TF-CBT (Type: ACTIVE_COMPARATOR): Standard TF-CBT consist of therapist-directly weekly in-office therapy based on the trauma-focused components of TF-CBT.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Bcl-XL_42-CAF09b Vaccination for Patients With Prostate Cancer With Lymph Node Metastases

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age ≥ 18 years~2. Histologically Verified Adenocarcinoma Prostatae~3. Diagnostic and / or histologically verified lymph node metastases~4. ECOG Performance Status ≤2~5. Primary anti-androgen treatment started~6. Adequate haematological, renal and hepatic function:~   1. Neutrophil granulocytes ≥ 1.5 x 109 / l~  2. Platelet counts ≥ 100 x 109 / l~  3. hemoglobin ≥ 5.6 mmol / l~  4. Serum creatinine ≤ 1.5 times upper normal limit~  5. AST or ALAT ≤ 2.5 times upper normal limit~  6. serum bilirubin ≤ 1.5 times upper normal limit~  7. Alkaline phosphatase ≤ 2.5 times upper normal limit~  8. INR \<1.5 / PP \<40~Exclusion Criteria:~1. Verified bone or visceral metastases~2. Serious allergy or previous anaphylactic reactions~3. Known hypersensitivity to any of the active substances or to any of the excipients.~4. Other malignant disease within the last three years, rendering planocellular and basocellular skin carcinoma~5. Known infection with HIV, hepatitis B and C virus, regardless of whether the infection is kept calm with medical treatment~6. Severe medical disorder, severe asthma, severe COPD, poorly regulated cardiovascular disease or diabetes~7. Active autoimmune disease, e.g. autoimmune neutropenia / thrombocytopenia or hemolytic anemia, systemic lupus erythematosus, scleroderma, myasthenia gravis, goodpasture syndrome, Addison's disease, Hashimoto's thyroiditis, active grave disease, morbus chrohn or ulcerative colitis~8. Major gastrointestinal surgical procedures within the last 3 months~9. Previous treatment with other cancer vaccine~10. Concomitant immunosuppressive treatment including prednisolone and methotrexate~11. Ongoing anticoagulant treatment (treatment with acetylsalicylic acid and clopidogrel is allowed)~12. Psychiatric disease which, according to the investigator's discretion, may affect compliance~13. Co-administration with other experimental drugs.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A: IM followed by IP (Type: EXPERIMENTAL): Will be administered first 3 vaccines biweekly IM and thereafter 3 vaccines biweekly IP.
- Arm B: IP followed by IM (Type: EXPERIMENTAL): Will be administered first 3 vaccines biweekly IP and thereafter 3 vaccines biweekly IM.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Determine the Efficacy and Safety of Lenalidomide in Patients With Mantle Cell NHL Who Have Relapsed or Progressed After Treatment With Bortezomib or Are Refractory to Bortezomib. The EMERGE Trial

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Biopsy proven mantle cell lymphoma~* Patients must have documents relapsed, refractory or PD after treatment with bortezomib~* Must have measureable disease on cross sectional imaging by CT~* Eastern Cooperative Oncology Group (ECOG) performance score 0,1 or 2~* Willing to follow pregnancy precautions~Exclusion Criteria:~* Any of the following laboratory abnormalities~  * Absolute neutrophil count (ANC) \< 1,500 cells/mm3 (1.5 x 109/L)~ * Platelet count \< 60,000/mm3 (60 x 109/L)~ * Serum aspartate transaminase/Serum glutamic oxaloacetic transaminase(AST/SGOT) or alanine transaminase/Serum glutamic pyruvic transaminase (ALT/SGPT) \> 3.0 x upper limit of normal (ULN), except in patients with documented liver involvement by lymphoma.~ * Serum total bilirubin \> 1.5 x ULN, except in cases of Gilbert's Syndrome and documented liver involvement by lymphoma.~ * Calculated creatinine clearance (Cockcroft-Gault formula) of \< 30 mL /min~ * Patients who are candidates for high dose chemotherapy/allogeneic stem cell transplant are not eligible~ * History of active central nervous system (CNS) lymphoma within the previous 3 months~ * Subjects not willing or unable to take deep vein thrombosis (DVT) prophylaxis~ * Prior history of malignancies, other than MCL, unless the patient has been free of the disease for ≥ 3 years~ * Positive Human immunodeficiency virus (HIV) or active Hepatitis B or C

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lenalidomide (Type: EXPERIMENTAL): Single agent Lenalidomide~Lenalidomide: 10mg or 25 mg oral capsules on days 1 to 21 of each 28 day cycle and dependent on renal function; Participants with normal renal function (defined as Creatinine Clearance(CrCl)) of ≥ 60 mL/min in this study) received 25 mg of lenalidomide daily, and those with moderate renal insufficiency (CrCl) ≥ 30 mL/min but \< 60 mL/min) were started at a 10-mg dose. Participants could continue to receive treatment until disease progression, development of unacceptable AEs, or voluntary withdrawal.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete